Scott Andrew M, Gunawardana Dishan H, Kelley Ben, Stuckey John G, Byrne Amanda J, Ramshaw Jayne E, Fulham Michael J
Centre for PET, Austin Hospital, Melbourne, Australia.
J Nucl Med. 2008 Sep;49(9):1451-7. doi: 10.2967/jnumed.108.051615. Epub 2008 Aug 14.
The aims of our study were to examine the impact of PET in changing management in patients with proven or suspected colorectal cancer recurrence and to assess the impact of management change on disease-free survival.
Symptomatic patients with a residual structural lesion suggestive of recurrent tumor (group A) or patients with pulmonary or hepatic metastases considered to be potentially resectable (group B) underwent PET scans. Pre-PET management plans were documented by referring clinicians unaware of the PET results, and follow-up to 12 mo was performed to determine actual management and clinical outcomes.
A total of 191 patients (118 men and 73 women; mean age, 66 y) were studied. PET detected additional sites of disease in 48.4% of patients in group A and in 43.9% of patients in group B. A change in planned management was documented in 65.6% of group A and in 49.0% of group B patients. These management plans were implemented in 96% of patients. Follow-up data in group A showed progressive disease in 60.5% of patients with additional lesions detected by PET, compared with conventional imaging, and in 36.2% of patients with no additional lesions detected by PET (P=0.04). In group B, progressive disease was identified in 65.9% of patients with additional lesions detected by PET and in 39.2% of patients with no additional lesions detected by PET (P=0.01). PET also provided valuable prognostic information on patients stratified into curative- or palliative-intent groups.
These data demonstrate the significant impact of PET on management and outcomes in patients with suspected recurrent colorectal cancer.
我们研究的目的是检查正电子发射断层扫描(PET)对已证实或疑似结直肠癌复发患者治疗方案改变的影响,并评估治疗方案改变对无病生存期的影响。
有提示肿瘤复发的残留结构病变的有症状患者(A组)或被认为可能可切除的肺或肝转移患者(B组)接受PET扫描。PET检查前的治疗方案由不了解PET结果的会诊医生记录,随访12个月以确定实际治疗方案和临床结果。
共研究了191例患者(118例男性和73例女性;平均年龄66岁)。PET在A组48.4%的患者和B组43.9%的患者中检测到额外的病灶部位。A组65.6%的患者和B组49.0%的患者记录有计划治疗方案的改变。这些治疗方案在96%的患者中得到实施。A组的随访数据显示,与传统成像相比,PET检测到额外病灶的患者中有60.5%疾病进展,PET未检测到额外病灶的患者中有36.2%疾病进展(P=0.04)。在B组中,PET检测到额外病灶的患者中有65.9%疾病进展,PET未检测到额外病灶的患者中有39.2%疾病进展(P=0.01)。PET还为分层为根治性或姑息性治疗意向组的患者提供了有价值的预后信息。
这些数据证明了PET对疑似复发性结直肠癌患者的治疗方案和预后有重大影响。